Candida albicans skin test antigen for cellular hypersensitivity - Biologic Drug Details

Summary for candida albicans skin test antigen for cellular hypersensitivity

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for candida albicans skin test antigen for cellular hypersensitivity

Physiological Effect	Cell-mediated Immunity Increased Histamine Release Increased IgG Production
Established Pharmacologic Class	Non-Standardized Fungal Allergenic Extract
Chemical Structure	Allergens Fungal Proteins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for candida albicans skin test antigen for cellular hypersensitivity Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for candida albicans skin test antigen for cellular hypersensitivity Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for candida albicans skin test antigen for cellular hypersensitivity Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Candida Albicans Skin Test Antigen for Cellular Hypersensitivity

Last updated: December 29, 2024

Introduction

The Candida albicans skin test antigen, marketed as CANDIN, is a biologic drug developed by Nielsen BioSciences, Inc. This product is used to assess cellular hypersensitivity to Candida albicans, a fungus that is commonly found on the human body. Here, we will delve into the market dynamics and financial trajectory of this biologic drug.

Market Need and Demand

Prevalence of Immune Disorders

The demand for CANDIN is driven by the need to assess and manage immune disorders. Many diseases and conditions, such as congenital immunodeficiencies, acquired immunodeficiencies, cancer, malnutrition, and viral and fungal infections, can alter the body's cell-mediated immunity response. This makes CANDIN a valuable tool in clinical settings[2][4].

Common Warts Treatment

Recently, CANDIN has been under investigation for its potential in treating common warts (Verruca vulgaris), a condition affecting approximately 10% of the global population. The ongoing Phase 3 clinical trial, in partnership with Maruho Co. Ltd., aims to evaluate the safety and efficacy of CANDIN for this indication, which could significantly expand its market[1].

Competitive Landscape

Unique Positioning

CANDIN is the only FDA-licensed Candida albicans extract-based skin testing antigen for intradermal injection. This unique positioning gives Nielsen BioSciences a competitive edge in the market for cell-mediated hypersensitivity testing[4].

Alternative Uses

CANDIN is often used as a control test for tuberculosis to rule out anergy, further solidifying its place in the diagnostic toolkit for immunologists and dermatologists. This versatility enhances its market appeal and usage[2][4].

Regulatory Environment

FDA Approval and Compliance

CANDIN has been approved by the FDA for its use in assessing cellular hypersensitivity to Candida albicans. The product must be administered intradermally according to specific guidelines to ensure reliable reactions and minimize adverse effects. Compliance with FDA regulations is crucial for maintaining market approval and trust[5].

Clinical Trials and Research

Ongoing Studies

The current Phase 3 clinical trial for the treatment of common warts is a significant milestone for Nielsen BioSciences. This study, conducted in the U.S. and Japan, aims to establish CANDIN as a viable treatment option for a condition with high unmet need. Positive outcomes could lead to expanded FDA approval and increased market share[1].

Previous Trials

Nielsen BioSciences has previously completed a Phase II clinical trial investigating CANDIN for the treatment of human papillomavirus (HPV) conditions, including Verruca vulgaris. These trials have laid the groundwork for the current Phase 3 study and demonstrate the company's commitment to research and development[1].

Safety and Efficacy

Side Effects and Safety Profile

While CANDIN is generally safe, it can cause local and systemic reactions. Common side effects include swelling, redness, itching, and blistering. Serious allergic reactions, such as anaphylaxis, can also occur, necessitating careful administration in a clinical setting with immediate access to emergency facilities[2][4].

Clinical Potency

Every lot of CANDIN is tested for consistency of potency, ensuring reliable clinical outcomes. This rigorous testing process contributes to the product's reputation for efficacy and safety[4].

Financial Trajectory

Revenue Streams

Nielsen BioSciences generates revenue from the sale of CANDIN for its approved use in assessing cellular hypersensitivity. Potential approval for the treatment of common warts could significantly boost revenue, given the large patient population affected by this condition.

Partnership and Licensing

The partnership with Maruho Co. Ltd. for the clinical development and potential commercialization of CANDIN in Japan adds another revenue stream. Licensing agreements can further expand the product's reach and financial impact[1].

Research and Development Costs

Investments in clinical trials, particularly the ongoing Phase 3 study, are substantial. However, successful outcomes can lead to significant returns through expanded market share and new indications.

Market Expansion Strategies

Global Reach

The ongoing clinical trial with a global reach, including sites in the U.S. and Japan, marks Nielsen BioSciences' first international clinical study. This expansion could pave the way for broader market penetration and increased revenue[1].

Diversification of Indications

Exploring additional indications beyond common warts, such as other HPV-related conditions, could further diversify the product's use and increase its market value.

Industry Expert Insights

Market Potential

"Given the high unmet need for effective treatments for common warts and the unique positioning of CANDIN, this product has significant market potential," said David P. Burney, PhD, MBA, President and Chief Operating Officer at Nielsen BioSciences. "We are excited about the potential to provide patients with an alternative to standard wart removal methods that can damage skin"[1].

Key Statistics

• Prevalence of Common Warts: Approximately 10% of the global population is affected by common warts[1].
• Clinical Trial Enrollment: The Phase 3 study aims to enroll patients across sites in the U.S. and Japan[1].
• Side Effects: Common side effects include swelling, redness, itching, and blistering, with serious allergic reactions possible[2][4].

Conclusion

The Candida albicans skin test antigen, CANDIN, is poised for significant market growth driven by its unique positioning, ongoing clinical trials, and potential expansion into new indications. As Nielsen BioSciences continues to invest in research and development, the financial trajectory of CANDIN is likely to be positive, especially if the Phase 3 trial for common warts yields favorable results.

Key Takeaways

• Unique Market Position: CANDIN is the only FDA-licensed Candida albicans extract-based skin testing antigen.
• Expanding Indications: Ongoing trials for the treatment of common warts could significantly expand its market.
• Global Reach: The product is being tested in a global clinical trial, marking Nielsen BioSciences' first international study.
• Safety and Efficacy: Rigorous testing ensures consistent clinical potency, though careful administration is necessary due to potential side effects.
• Financial Potential: Successful clinical trials and market expansion could lead to substantial revenue growth.

FAQs

Q: What is CANDIN used for? A: CANDIN is used to assess cellular hypersensitivity to Candida albicans and is also under investigation for the treatment of common warts (Verruca vulgaris)[1][4].

Q: Is CANDIN FDA-approved? A: Yes, CANDIN is FDA-approved for its use in assessing cellular hypersensitivity to Candida albicans[4].

Q: What are the common side effects of CANDIN? A: Common side effects include swelling, redness, itching, and blistering. Serious allergic reactions can also occur[2][4].

Q: Who is partnering with Nielsen BioSciences for the clinical development of CANDIN? A: Maruho Co. Ltd. is partnering with Nielsen BioSciences for the clinical development and potential commercialization of CANDIN in Japan[1].

Q: What is the current stage of clinical trials for CANDIN in treating common warts? A: The product is currently in a Phase 3, randomized, double-blind, placebo-controlled study for the treatment of common warts[1].

Sources

1. Nielsen BioSciences: News - Nielsen Biosciences.
2. MedicineNet: Candida albicans skin test antigen - MedicineNet.
3. CDC: 2021 NHSN Patient Safety Component Manual - CDC.
4. Nielsen BioSciences: CANDIN - Candida Albicans Skin Test Antigen for Cellular Immunity.
5. FDA: Package Insert - CANDIN - FDA.